Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress in research of pancreatic tumor markers

( views:197, downloads:26 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 34

DOI:: 10.3969/j.issn.1009-3079.2007.34.009

Key Word:: 胰腺炎;肿瘤标志物

Abstract：胰腺癌早期诊断困难,预后差,患者5年生存率小于5%.新近研究报道,早期发现并切除的胰腺癌患者5年生存率为15%-40%,因此早期诊断胰腺癌能够有效挽救患者生命.目前一些常用的肿瘤标志物在胰腺癌的诊断、治疗监测及预后评估中起到了重要作用,但这些指标的特异性和敏感性尚不能满足临床的需要.因此迫切需要寻找新的肿瘤标志物并建立联合诊断的方法来进一步提高胰腺癌的诊疗水平.

Reference

[1]C E, Forsmark,L, Lambiase,S B, Vogel.Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.[J].1994,9(6).
[2]M, Ventrucci,G M, Ubalducci,A, Cipolla,etc.Serum CA 242: the search for a valid marker of pancreatic cancer.[J].1998,36.
[3]Saad ED,Machado MC,Wajsbrot D,etc.Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.[J].2002,32(1).
[4]Michael J, Swartz,Surinder K, Batra,Grish C, Varshney,etc.MUC4 expression increases progressively in pancreatic intraepithelial neoplasia.[J].2002,117(5).
[5]Pentti A. Pasanen,Matti Eskelinen,Kaarina Partanen,etc.Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma[J].1994,120(8).
[6]R E, Ritts,D M, Nagorney,D J, Jacobsen,etc.Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.[J].1994,9.
[7]W, Zhou,L J, Sokoll,D J, Bruzek,etc.Identifying markers for pancreatic cancer by gene expression analysis.[J].1998,7.
[8]Guo J,Hammer J,Korc M,etc.Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.[J].2004,23(1).
[9]Eugene P. DiMagno,Howard A. Reber,Margaret A. Tempero.AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma[J].1999,117(6).
[10]Haglund C,Lundin J,Kuusela P,etc.CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA[J].1994.
[11]S T, Chari,G G, Klee,L J, Miller,etc.Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer.[J].2001,121(3).
[12].Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers.[J].1999,19(4A).
[13]S, Shahangian,H A, Fritsche,J I, Hughes,etc.Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas.[J].1989,35.
[14]N, Parker,C A, Makin,C K, Ching,etc.A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer.[J].1992,70(5).
[15]Calder F,Yiannakou JY,Newland P,etc.Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer.[J].1997,349(9049).
[16]F, Safi,W, Schlosser,S, Falkenreck,etc.CA 19-9 serum course and prognosis of pancreatic cancer.[J].1996,20.
[17]Armstrong TD,Huang LQ,Thomas AM,etc.Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.[J].2004,200(3).
[18]T A, Brentnall,M P, Bronner,D R, Byrd,etc.Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer.[J].1999,131.
[19]Carpelan Holmstrom M,Louhimo J,Stenman UH,etc.CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.[J].2002,22(4).
[20]Cristina Balagué,Jean-Pierre Audié,Nicole Porchet,etc.In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues[J].1995,109(3).
[21]Glimelius Bengt,Hoffman Katarina,Einarsson Roland,etc.Monitoring Palliative Chemotherapy in Advanced Gastrointestinal Cancer Using Serial Tissue Polypeptide Specific Antigen (Tps) Measurements[J].1996.
[22]Hong-Ja Kim,Myung-Hwan Kim,Seung-Jae Myung,etc.A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve[J].1999,94(7).
[23]Chambers AF,Rittling SR.Role of osteopontin in tumour progression.[J].2004,90(10).
[24]Schneider J,Schulze G.Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.[J].2003,23(6D).
[25]Gansauge F,Gansauge S,Parker N,etc.CAM 17.1 - A new diagnostic marker in pancreatic cancer[J].1996.
[26]Micke O,Kurowski R,Horst E,etc.Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.[J].2003,57(1).
[27]Strehl J,Sauerbruch T,Ziske C,etc.Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.[J].2003,89(8).
[28]Eccleston, D. W.,Milton, J. D.,Hoffman, J.,etc.Pancreatic Tumour Marker Anti-Mucin Antibody CAM 17.1 Reacts with a Sialyl Blood Group Antigen, Probably I, Which Is Expressed throughout the Human Gastrointestinal Tract.[J].1998,59(6).
[29]K A, Furger,R K, Menon,A B, Tuck,etc.The functional and clinical roles of osteopontin in cancer and metastasis.[J].2001,1(5).
[30]Del Giudice G,Navaglia F,D'Angeli F,etc.Is CA242 really a new tumour marker for pancreatic adenocarcinoma?[J].1995,52(1).
[31]M, Hy?ty,H, Hy?ty,R K, Aaran,etc.Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.[J].1992,158(3).
[32]W, Steinberg.The clinical utility of the CA 19-9 tumor-associated antigen.[J].1990,85.
[33]Canto MI,Goggins M,Hruban RH,etc.Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.[J].2006,4(6).
[34]Heinemann V,Schermuly MM,Stieber P,etc.CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.[J].1999,19(4A).
[35]Yamaguchi Y,Motoo Y,Watanabe H,etc.Serum tumor markers and molecular biological diagnosis in pancreatic cancer.[J].2004,28(3).
[36]Paik SW,Rhee JC,Choi KW,etc.Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.[J].2004,19(2).
[37]Kawa S,Oguchi H,Kobayashi T,etc.Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype[J].1991.
[38]Koopmann J,Hruban RH,Goggins M,etc.Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma.[J].2005,18(6).